The global Peptide Therapeutics Market had a value of USD 25.35 Billion in 2018 and is projected to reach USD 50.60 Billion by the year 2026, with a compound annual growth rate (CAGR) of 9.0%. Peptides are naturally occurring biological molecules that play a crucial role in various biological activities within living organisms. Due to their function as signaling molecules for numerous physiological functions, they present an opportunity in the field of therapeutics to mimic natural pathways.

Peptide drugs act as replacement therapies, providing support or nourishment to peptide hormones when their endogenous levels decline. The first peptide therapeutic was derived from whole animal tissue, followed by the purification of Adrenocorticotrophic hormone (ACTH), which eventually led to the development of therapeutic insulin for treating diabetic patients in the 1920s. The market growth is expected to be supported by factors such as improved purification workflows, integration of automation, and reduced waste generation.

Get a sample of the report @ https://www.reportsanddata.com/download-free-sample/2770

Companies considered and profiled in this market study

Sanofi (Australia), Teva Inc (Israel), Novo Nordisk Inc,  (Denmark), Takeda  (Japan), Eli Lily  (U.S.), Astra Zeneca (UK), Novartis (Switzerland), Shire (US) Abbvie (US), Ipsen (France) Allergen (Ireland ), Ferring (Switzerland), Merck  (United States), The Medicines  (United States), Roche (Switzerland) Johnson and Johnson (United States).

To know more about the report @ https://www.reportsanddata.com/report-detail/peptide-therapeutics-market

The Peptide Therapeutics Market is influenced by several driving factors and restraints.

Driving Factors:

  1. Increasing Prevalence of Chronic Diseases: The rising incidence of chronic diseases such as cancer, diabetes, cardiovascular disorders, and metabolic disorders has led to a growing demand for peptide therapeutics. Peptides offer targeted and specific treatments for these conditions, driving market growth.
  2. Advancements in Peptide Synthesis Technologies: The development of innovative peptide synthesis techniques, including solid-phase peptide synthesis (SPPS), has significantly improved the production and purification of peptides. These advancements have facilitated the manufacturing process, leading to increased availability and accessibility of peptide therapeutics.
  3. Growing Research and Development Activities: Extensive research and development efforts in the field of peptide therapeutics have resulted in the discovery of novel peptide-based drugs. The exploration of new therapeutic targets and the optimization of peptide structures have expanded the range of applications and potential market opportunities.
  4. Favorable Regulatory Environment: Regulatory agencies have recognized the importance of peptide therapeutics and have streamlined the approval process for peptide drugs. The establishment of clear guidelines and expedited pathways for peptide-based treatments has fostered market growth and encouraged innovation in the field.

Restraints:

  1. High Development Costs: The development and commercialization of peptide therapeutics involve substantial investment in research, clinical trials, and manufacturing infrastructure. The high costs associated with these processes pose a significant challenge, especially for small and medium-sized enterprises, limiting market growth.
  2. Limited Oral Bioavailability: Peptides are susceptible to degradation and have low oral bioavailability, making it challenging to administer them orally. This limitation necessitates alternative administration routes such as injections, implants, or inhalation, which can affect patient compliance and restrict the market potential.
  3. Stringent Regulatory Requirements: While favorable regulatory frameworks exist, the stringent regulatory requirements for peptide therapeutics can pose hurdles for market players. Compliance with rigorous safety and efficacy standards, as well as extensive documentation and testing, can result in delays in product development and approval.
  4. Potential Side Effects and Immunogenicity: Peptide therapeutics may exhibit side effects and immunogenic responses in some patients. The potential for adverse reactions and the development of antibodies against peptide drugs can impact their efficacy and overall market acceptance.

Request a customization of the report @ https://www.reportsanddata.com/request-customization-form/2770

About Us:

Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target and analyze consumer behavior shifts across demographics, across industries and help client’s make a smarter business decision. We offer market intelligence studies ensuring relevant and fact-based research across a multiple industries including Healthcare, Technology, Chemicals, Power and Energy. We consistently update our research offerings to ensure our clients are aware about the latest trends existent in the market.


Contact Us:

John W

(Head of Business Development)

Reports and Data | Web: www.reportsanddata.com

Direct Line: +1-212-710-1370

E-mail: sales@reportsanddata.com

Blogs | Press Release | Industry News | Our competencies

Browse More Upcoming Reports @ https://www.reportsanddata.com/upcoming-reports

Browse More Latest Reports @ https://www.reportsanddata.com/report

Browse More Reports:

Laboratory Filtration Market

Crohn's Disease Drug Market

Ankylosing Spondylitis Drugs Market

Transcranial Magnetic Stimulators Market

Orthopedic Biomaterials Market

Drug Addiction Treatment Market